Author: Novo Nordisk

Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with hemophilia A as published in the Journal of Thrombosis and Haemostasis

September 17, 2026
Novo Nordisk’s Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US

August 11, 2026

Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with hemophilia A as published in the Journal of Thrombosis and Haemostasis